CERC Key Statistics, Chart & Performance
The current stock price of CERC is 2.93 null. In the past month the price increased by 6.55%. In the past year, price increased by 15.35%.
CERC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.39 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.73 | 493.40B | ||
| MRK | MERCK & CO. INC. | 12.36 | 270.22B | ||
| PFE | PFIZER INC | 7.95 | 144.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.3 | 110.79B | ||
| ZTS | ZOETIS INC | 20.4 | 57.00B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.89 | 23.46B | ||
| VTRS | VIATRIS INC | 5.32 | 14.28B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.79 | 11.83B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.59B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.36B |
Related stock screener links
About CERC
Company Profile
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2015-11-13. The firm is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The firm is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
Company Info
Cerecor Inc
540 Gaither Rd Ste 400
Rockville MARYLAND 20850 US
CEO: Michael Cola
Employees: 32
Phone: 14105228707.0
Cerecor Inc / CERC FAQ
What does Cerecor Inc do?
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2015-11-13. The firm is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The firm is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
What is the stock price of Cerecor Inc today?
The current stock price of CERC is 2.93 null. The price decreased by -1.68% in the last trading session.
Does Cerecor Inc pay dividends?
CERC does not pay a dividend.
What is the ChartMill technical and fundamental rating of CERC stock?
CERC has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for Cerecor Inc?
Cerecor Inc (CERC) operates in the Health Care sector and the Pharmaceuticals industry.
What is the expected growth for CERC stock?
The Revenue of Cerecor Inc (CERC) is expected to decline by -12.27% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CERC Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CERC. When comparing the yearly performance of all stocks, CERC turns out to be only a medium performer in the overall market: it outperformed 48.14% of all stocks.
CERC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CERC. CERC may be in some trouble as it scores bad on both profitability and health.
CERC Financial Highlights
Over the last trailing twelve months CERC reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS decreased by -49.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1194.83% | ||
| ROA | -119.98% | ||
| ROE | N/A | ||
| Debt/Equity | 0.79 |
CERC Forecast & Estimates
4 analysts have analysed CERC and the average price target is 6.63 null. This implies a price increase of 126.28% is expected in the next year compared to the current price of 2.93.
For the next year, analysts expect an EPS growth of 4.09% and a revenue growth -12.27% for CERC